For example, Kashihara et al and other studies demonstrated that high CD133 expression in CRC correlated with poor clinical outcomes.[10–13] Nevertheless, Hong et al and other studies showed that CD133-negative patients exhibited a poor prognosis.[14,15] Therefore, we performed a meta-analysis to elucidate the correlation between CD133 and clinicopathological features of CRC, and determine the value of CD133 as a prognostic marker for CRC. The gene discussed is PROM1; the disease is colorectal carcinoma.